More than one in ten people with eating disorders who participated in a newly published study reported misusing GLP-1 receptor agonist medications — the drug class that includes semaglutide, sold under the brand names Ozempic and Wegovy — by taking doses that differed from what was prescribed. That figure, combined with the finding that eating disorder patients are using these drugs at more than twice the rate of the general population, has prompted researchers and clinicians to call the current prescribing landscape clinically urgent.

The Core Statistics — and Why They Matter to Prescribers

According to research reported by MedPage Today, people with eating disorders are using GLP-1 medications at more than double the rate seen in the broader population — a disparity researchers describe not as coincidental but as structurally predictable, given how these drugs work and how eating disorder cognition operates. Approximately 10 percent of study participants with eating disorders reported misusing GLP-1 medications, including taking higher or lower doses than prescribed. That behavioral pattern — deliberately altering a prescribed dose to achieve a specific effect on the body — directly mirrors the compensatory and restrictive behaviors that define eating disorder symptomatology.

Nearly one in ten respondents also reported using noncommercial compounded versions of these drugs: formulations produced outside the regulated pharmaceutical supply chain. Compounded products carry no guarantee of dose accuracy, sterility, or consistent active ingredient concentration — a pharmacological wildcard that is particularly dangerous in a population already at elevated medical risk.

Perhaps most consequentially, Penn Medicine has noted that no standardized screening protocol currently exists to identify eating disorder risk before a clinician writes a GLP-1 prescription. That structural gap — less visible when these drugs were confined to endocrinology offices — has become increasingly consequential as semaglutide prescriptions have migrated into primary care, telehealth platforms, and medical spas where clinical encounters are shorter and psychiatric histories are rarely explored.

What “Food Noise” Actually Means — and Why the Brain Is Central

“Food noise” is a colloquial term for the persistent, intrusive preoccupation with food, hunger, and eating that many people experience throughout the day. It is not a clinical diagnosis but a lived description — the mental loop of wondering what to eat next, when the next meal is coming, whether a food choice was correct. GLP-1 drugs appear to quiet this mental chatter not simply by slowing digestion but by acting directly on reward and appetite circuits in the brain.

GLP-1 receptor agonists work by mimicking glucagon-like peptide-1, a hormone naturally released in the gut after eating. They slow gastric emptying, stimulate insulin release, and — critically — bind to receptors in the hypothalamus and in dopamine-rich areas of the brain that govern craving and satiety. This central nervous system action is why the drugs feel psychologically different from simply eating a large meal: they alter the neural experience of wanting food, not just the physical sensation of fullness.

For most people, that suppression of food noise registers as relief. For someone whose brain is already neurobiologically dysregulated by anorexia nervosa or another restrictive eating disorder, the same pharmacological effect can function very differently. Rather than correcting a disordered relationship with hunger, it can provide what feels like chemical permission to eat even less — reinforcing restriction rather than interrupting it. As the National Eating Disorders Association has outlined, distinguishing between therapeutic appetite modulation and pathological restriction reinforcement is the central clinical tension researchers are now working to resolve.

A Drug Designed for Metabolic Disease Meets a Population It Wasn’t Built For

GLP-1 receptor agonists were developed and approved primarily for type 2 diabetes management and, subsequently, for chronic weight management in people with obesity — populations whose clinical profile is, in most respects, the opposite of someone with restrictive anorexia nervosa. The therapeutic goal in metabolic disease is to reduce excess caloric intake and improve insulin sensitivity. In restrictive eating disorders, the pathology is already one of dangerous undereating; adding profound pharmaceutical appetite suppression does not correct that pathology — it can entrench it.

For individuals with binge-purge subtypes of eating disorders, the dynamic is different but equally fraught. GLP-1 medications may be misused as a compensatory behavior — a pharmacological substitute for purging — rather than as a medically supervised treatment aimed at metabolic health. The appeal is understandable from within eating disorder logic: a drug that reliably reduces the drive to eat is, to a brain organized around restriction or compensatory control, an attractive tool regardless of medical intent.

The study findings underscore that eating disorder populations are actively accessing these medications through multiple channels, including compounded products and direct-to-consumer telehealth services, often without the prescribing clinician having any awareness of the patient’s psychiatric history. ABC News’s coverage of the findings highlights how this access landscape has outpaced the clinical infrastructure designed to manage it safely.

The Mixed Signal From Binge-Eating Research

Not all the evidence points toward harm, and intellectual honesty requires stating that clearly. GLP-1 receptor agonists have been reported in some trials to reduce binge-eating episodes, which has led some researchers to propose a potential therapeutic role for these drugs in specific eating disorder presentations — particularly binge-eating disorder, where the mechanism of appetite and reward modulation is at least directionally aligned with treatment goals.

However, as a review published in the peer-reviewed literature on GLP-1 receptor agonists in eating disorder contexts notes, this evidence base is limited and often inconsistent, hampered by small sample sizes, short follow-up periods, and the absence of rigorous psychiatric screening in most weight-management trials. The patients enrolled in obesity trials are not representative of eating disorder populations, and the outcome measures used — body weight, glycemic control — are not the same as eating disorder recovery endpoints.

The gap between “this drug reduced binge episodes in a small, unscreened trial” and “this drug is safe and effective for eating disorder treatment” is substantial. Conflating the two in clinical shorthand or in popular media carries real risk, particularly when patients with eating disorders are already motivated to interpret ambiguous evidence in ways that serve the disorder rather than their health. Researchers have concluded that GLP-1 receptor agonists have the potential to be a therapeutic option in some eating disorder cases, but that inappropriate use may increase the morbidity of those same disorders — a duality that demands clinical precision rather than blanket prohibition or blanket endorsement.

Why Restrictive Disorders Represent the Sharpest Risk

Misuse of GLP-1 drugs is particularly concerning in the context of restrictive eating disorders like anorexia nervosa, which already carries the highest mortality rate of any psychiatric condition. That baseline risk — from cardiac complications, electrolyte imbalances, and organ failure caused by severe malnutrition — is meaningfully worsened by any intervention that further suppresses the drive to eat.

Anorexia nervosa involves a neurobiologically distinct relationship with hunger. Many patients with active anorexia report blunted hunger signals or, in some cases, a rewarding quality to the physical sensation of restriction — a paradox that reflects genuine neurological dysregulation rather than conscious choice. For these patients, a drug that further quiets appetite signals may not feel dangerous. It may feel desirable, even therapeutic, in a way that is entirely consistent with how the disorder distorts perception. That subjective experience of relief is precisely what makes the misuse pattern clinically difficult to detect and patient-reported safety data clinically unreliable in this population.

The compounded-product finding compounds this risk in a concrete way. Noncommercial formulations of semaglutide or tirzepatide produced outside the regulated pharmaceutical supply chain offer no guarantee that the active ingredient concentration matches what is stated on the label — meaning a patient could be receiving a fraction of the intended dose or a dangerous excess, with no mechanism for the prescribing clinician to know.

The Screening Gap: A System That Wasn’t Built for This Moment

Standard prescribing checklists for semaglutide focus on cardiovascular risk factors, pancreatitis history, and thyroid concerns. They do not ask about eating disorder history, body image disturbance, or patterns of weight-control behavior. This omission was arguably tolerable when GLP-1 medications were confined to specialist settings with longer clinical relationships and more complete psychiatric histories. It is not tolerable now.

The rise of direct-to-consumer telehealth prescribing has compressed the clinical encounter to its minimum viable form. A prescriber who spends seven minutes with a patient via video call, reviewing a symptom checklist optimized for metabolic risk, is not positioned to detect the subtle signs of a restrictive eating disorder — the minimizing language, the framing of restriction as discipline, the absence of concern about low weight. Coverage of the new study highlights how this structural compression has created a prescribing environment in which vulnerable patients can access powerful appetite suppressants with minimal psychiatric scrutiny.

Eating disorder specialists and obesity medicine clinicians are now calling for cross-specialty collaboration on a shared screening standard — one that neither pathologizes every patient seeking weight management nor ignores the meaningful subset for whom GLP-1 medications could trigger or worsen a psychiatric crisis. Emerging research on the dual role of GLP-1 receptor agonists in weight management and eating disorder contexts is beginning to supply the clinical framework that practical screening tools will need to draw from. The challenge is translating that framework into standard practice before the prescribing volume grows further.

What Responsible Prescribing Looks Like From Here

The researchers’ core conclusion is not that GLP-1 drugs are categorically dangerous for people with eating disorders. It is that the absence of structured risk stratification makes the current prescribing landscape unnecessarily hazardous for a vulnerable population — and that this is a correctable problem.

For clinicians, the immediate actionable step is incorporating validated eating disorder screening instruments — such as the SCOFF questionnaire or the Eating Disorder Examination Questionnaire (EDE-Q) — into GLP-1 eligibility assessments. A positive screen should function as a flag for specialist consultation rather than an automatic contraindication, recognizing that the clinical picture is complex and that some patients with eating disorder histories may still be appropriate candidates for these medications under careful psychiatric supervision. Clinicians working in eating disorder treatment have also emphasized that the framing used in patient-facing materials matters: language that glamorizes appetite suppression can resonate dangerously with eating disorder cognition even when it is aimed at a general audience.

For patients and families, the public-health implication is equally direct. The “food noise” framing, while mechanistically useful, can inadvertently make appetite suppression sound appealing in ways that mirror core eating disorder desires. The experience of silence around food — the relief of not wanting — sounds positive in a general wellness context. Inside an eating disorder, that same silence is not relief. It is reinforcement. Clinician communication and patient-facing materials should name that distinction explicitly and consistently, rather than leaving patients to draw their own conclusions from marketing language and social media accounts.

The current study represents early-stage evidence in a rapidly evolving clinical and commercial landscape. What it establishes most firmly is not a final answer about GLP-1 safety in eating disorder populations, but the urgent need for larger, prospective, psychiatrically rigorous trials — and for the clinical infrastructure to protect patients while that evidence is being assembled. The prescribing volume will not wait for the research to catch up. The screening standards need to move first.